Pillar · Biotech Investing
Biotech Due Diligence Checklist: How to Evaluate a Drug Pipeline and Probability of Approval
Most biotech investors skip due diligence and pay the price. This step-by-step checklist walks you through everything yo...
Start here
Pillar · Clinical Readouts
How to Read Biotech Clinical Trial Data: Phase 1, 2, 3 Results Explained for Investors
Clinical trial data is the single most important factor in biotech investing, but most investors struggle to read it. Th...
FDA & PDUFA Calendar
IGALMI PDUFA for Agitation: Biotech Catalysts Oct 26, 2026
BioXcel's IGALMI PDUFA on Nov 14 could reshape agitation treatment, with a 10% approval chance. Explore the potential impact on the market....
Clinical Readouts
MN-166 in ALS: Phase 2 and 3 Readouts Oct 19, 2026
MN-166's Phase 2 readout is set for April 2027, with a -58.8% run-up. We analyze the implications for investors and the upcoming clinical trial results....
Therapeutic Areas
Top Pharma Companies by Revenue in 2025, Drug by Drug
The top 15 pharma companies made $756B from drugs in 2025. GLP-1s brought in $77.3B, and half of what they are testing next is cancer....
FDA & PDUFA Calendar
FDA Calendar Q4 2026: Key PDUFA Dates and Upcoming Approvals
Q4 2026 FDA calendar: all 43 PDUFA dates and FDA decisions through March 2027, with the modeled odds of approval for every drug. Next: bepirovirsen, October 26....
FDA & PDUFA Calendar
BIOA APJ program: Biotech Catalysts Oct 19, 2026
HUMA's ATEV for hemodialysis in female patients has a PDUFA on Oct 22, 2026. Explore other key biotech catalysts to watch in our latest analysis....
FDA & PDUFA Calendar
IGALMI PDUFA for Bipolar Disorders: Biotech Catalysts Oct 12, 2026
On November 14, 2026, IGALMI faces a PDUFA decision for bipolar disorders. Explore biotech catalysts to watch this week....
FDA & PDUFA Calendar
SIL204 Phase 2/3 for Locally Advanced Pancreatic Cancer: Biotech Catalysts Oct 5, 2026
SIL204's Phase 2/3 trial for pancreatic cancer could reshape treatment options. Explore catalysts shaping the biotech landscape this October....
FDA & PDUFA Calendar
Biotech Penny Stock Catalysts: FDA Calendar and PDUFA Dates for Small-Cap Pharma Stocks
With a 72% approval probability for ZYNLONTA, biotech penny stock catalysts are on the rise. Discover key upcoming events and their potential impact....
FDA & PDUFA Calendar
FDA Calendar October 2026: Key PDUFA Dates and Insights
On October 26, 2026, bepirovirsen could reshape chronic hepatitis B treatment. Explore our analysis of pivotal FDA approval dates this month....